Table 1 Association of KRAS and TP53 co-mutation status with patients and tumour characteristics in the Heidelberg cohort of 713 stage IV lung adenocarcinoma (HD-ICI).
From: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Variable | Value | KRASwt/TP53wt | KRASwt/TP53mut | KRASmut/TP53wt | KRASmut/TP53mut | p |
|---|---|---|---|---|---|---|
Prevalence | 191 (26.8%) | 162 (22.7%) | 237 (33.2%) | 123 (17.3%) | ||
Age | Mean ± sd | 66.2 ± 9.6 | 65 ± 8.9 | 64.3 ± 9 | 64.7 ± 7.7 | 0.072 |
Sex | 0.0039 | |||||
Male | 107 (27%) | 105 (26.5%) | 131 (33.1%) | 53 (13.4%) | ||
Female | 84 (26.5%) | 57 (18%) | 106 (33.4%) | 70 (22.1%) | ||
Smoking | 4.9e-07 | |||||
Smoker | 137 (22.7%) | 141 (23.4%) | 211 (35%) | 114 (18.9%) | ||
Never/light | 54 (49.1%) | 21 (19.1%) | 26 (23.6%) | 9 (8.2%) | ||
PD-L1 | 0.0035 | |||||
≥ 50% | 38 (18.4%) | 50 (24.3%) | 68 (33%) | 50 (24.3%) | ||
≥ 1–49% | 79 (28.3%) | 59 (21.1%) | 94 (33.7%) | 47 (16.8%) | ||
negative | 66 (32.5%) | 50 (24.6%) | 66 (32.5%) | 21 (10.3%) |
